Johanna E. Bruijnes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Johanna E. Bruijnes has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Alwin A.H.A. Derijck
Amsterdam Reproduction and Development Research Institute, Amsterdam, Netherlands
1 shared publication- Barry J. Ruijter
Department of Clinical Neurophysiology, Technical Medical Centre, University of Twente, Enschede, The Netherlands
1 shared publication - Bettine Anna Hildegard Vosse
Centre for Home Mechanical Ventilation Maastricht (CHMV) Maastricht University Medical Centre Maastricht the Netherlands
1 shared publication Catharina G. Faber
Department of Neurology and MHeNS Mental Health and Neuroscience Research Institute, Maastricht University Medical Centre+, Maastricht, Netherlands
1 shared publication- Catharina Gerritdina Faber
Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands
1 shared publication D. van As
Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (6) , e200454
Clinical Heterogeneity in Myotonic Dystrophy Type 1
Background and ObjectivesMyotonic dystrophy type 1 (DM1) is a genetic multisystem disorder with a wide variability in symptom severity and symptom co-occurrence. This study aimed to identify homoge...
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (6) , e200454
Open AccessClinical Heterogeneity in Myotonic Dystrophy Type 1
Background and ObjectivesMyotonic dystrophy type 1 (DM1) is a genetic multisystem disorder with a wide variability in symptom severity and symptom co-occurrence. This study aimed to identify homoge...
- Open Access
- 2 November 2026
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
Preimplantation genetic testing in myotonic dystrophy type 1: outcomes in a nationwide Dutch cohort
- 2 November 2026
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
Open AccessPreimplantation genetic testing in myotonic dystrophy type 1: outcomes in a nationwide Dutch cohort
- 2 November 2023
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (3) , 1267-1276
Neurological complications of excessive recreational nitrous oxide use: a case series based on a text mining algorithm
Background The recreational use of nitrous oxide (N2O) has gained popularity over recent years. We present a case series of excessive N2O users with neurological complications. Methods In this retrospective three-centre study, we used a text mining algorithm to search for patients who used N2O recreationally and visited a neurologist. Results We identified 251 patients. The median duration of N2O use was 11 months (interquartile range [IQR], 3–24) and the median amount of N2O used per occasion 1.6 kg (IQR 0.5–4.0). Clinically, polyneuropathy (78%), myelopathy (41%), and encephalopathy (14%) were the most common diagnoses. An absolute vitamin B12 deficiency of < 150 pmol/L was found in 40% of cases. In 90%, at least one indicator of functional vitamin B12 status (vitamin B12, homocysteine, or methylmalonic acid) was abnormal. MRI showed signs of myelopathy in 30/55 (55%) of cases. In 28/44 (64%) of those who underwent electromyography, evidence of axonal polyneuropathy was found. Most (83%) patients were treated with vitamin B12 supplementation, and 23% were admitted to the hospital. Only 41% had follow-up for ≥ 30 days, and 79% of those showed partial or complete recovery. Conclusions In this case series of excessive N2O users, we describe a high prevalence of polyneuropathy, myelopathy, and encephalopathy. Stepwise testing for serum levels of vitamin B12, homocysteine, and methylmalonic acid may support the clinical diagnosis. Due to low sensitivity, MRI of the spinal cord and electromyography have limited value. Effective treatment should incorporate supplementation of vitamin B12 and strategies to prevent relapses in N2O use.
- 2 November 2023
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (3) , 1267-1276
Neurological complications of excessive recreational nitrous oxide use: a case series based on a text mining algorithm
Background The recreational use of nitrous oxide (N2O) has gained popularity over recent years. We present a case series of excessive N2O users with neurological complications. Methods In this retrospective three-centre study, we used a text mining algorithm to search for patients who used N2O recreationally and visited a neurologist. Results We identified 251 patients. The median duration of N2O use was 11 months (interquartile range [IQR], 3–24) and the median amount of N2O used per occasion 1.6 kg (IQR 0.5–4.0). Clinically, polyneuropathy (78%), myelopathy (41%), and encephalopathy (14%) were the most common diagnoses. An absolute vitamin B12 deficiency of < 150 pmol/L was found in 40% of cases. In 90%, at least one indicator of functional vitamin B12 status (vitamin B12, homocysteine, or methylmalonic acid) was abnormal. MRI showed signs of myelopathy in 30/55 (55%) of cases. In 28/44 (64%) of those who underwent electromyography, evidence of axonal polyneuropathy was found. Most (83%) patients were treated with vitamin B12 supplementation, and 23% were admitted to the hospital. Only 41% had follow-up for ≥ 30 days, and 79% of those showed partial or complete recovery. Conclusions In this case series of excessive N2O users, we describe a high prevalence of polyneuropathy, myelopathy, and encephalopathy. Stepwise testing for serum levels of vitamin B12, homocysteine, and methylmalonic acid may support the clinical diagnosis. Due to low sensitivity, MRI of the spinal cord and electromyography have limited value. Effective treatment should incorporate supplementation of vitamin B12 and strategies to prevent relapses in N2O use.